222 related articles for article (PubMed ID: 22387202)
1. [Vocal cord paralysis secondary to vincristine].
Nafil H; Tazi I; Mahmal L
Rev Neurol (Paris); 2012 May; 168(5):464-5. PubMed ID: 22387202
[No Abstract] [Full Text] [Related]
2. Low-dose vincristine-associated bilateral vocal cord paralysis.
Ryan SP; DelPrete SA; Weinstein PW; Erichson RB; Bar MH; Lo KM; Cohen NS; Tepler I
Conn Med; 1999 Oct; 63(10):583-4. PubMed ID: 10578547
[TBL] [Abstract][Full Text] [Related]
3. [Picture in clinical hematology].
Hatsuse M; Shimazaki C; Yumiba T
Rinsho Ketsueki; 2013 Jan; 54(1):1. PubMed ID: 24015417
[No Abstract] [Full Text] [Related]
4. Reversible posterior leukoencephalopathy syndrome following R-CHOP therapy for diffuse large B-cell lymphoma.
Hosoi M; Yamamoto G; Imai Y; Kurokawa M
Ann Hematol; 2010 Feb; 89(2):207-8. PubMed ID: 19582454
[No Abstract] [Full Text] [Related]
5. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Coiffier B; Lepage E; Briere J; Herbrecht R; Tilly H; Bouabdallah R; Morel P; Van Den Neste E; Salles G; Gaulard P; Reyes F; Lederlin P; Gisselbrecht C
N Engl J Med; 2002 Jan; 346(4):235-42. PubMed ID: 11807147
[TBL] [Abstract][Full Text] [Related]
6. Low-dose vincristine-associated bilateral vocal cord paralysis.
Alfredsunder P; Hochman MC; Kaplan BH
N Y State J Med; 1992 Jun; 92(6):268-9. PubMed ID: 1641212
[No Abstract] [Full Text] [Related]
7. Vocal cord paralysis during the treatment of mantle cell lymphoma with vincristine.
Yalin SF; Trabulus S; Yalin AS; Yalin GY; Ongoren S; Altiparmak MR
Int J Clin Pharm; 2013 Jun; 35(3):306-8. PubMed ID: 23338712
[TBL] [Abstract][Full Text] [Related]
8. Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma.
Furman RR; Martin P; Ruan J; Cheung YK; Vose JM; LaCasce AS; Elstrom R; Coleman M; Leonard JP
Cancer; 2010 Dec; 116(23):5432-9. PubMed ID: 20665890
[TBL] [Abstract][Full Text] [Related]
9. [Vincristine-induced recurrent laryngeal nerve paralysis].
Núñez E; Solano D; Arreita A; Franco-Vicario R; Miguel F
Rev Clin Esp; 1992 Mar; 190(4):214-5. PubMed ID: 1589626
[No Abstract] [Full Text] [Related]
10. CHOP chemotherapy as standard therapy for treatment of patients with diffuse histiocytic lymphoma.
Fisher RI
Important Adv Oncol; 1990; ():217-25. PubMed ID: 2182520
[No Abstract] [Full Text] [Related]
11. Genetic polymorphism at
Bashash M; Connors JM; Gascoyne RD; Meissner B; Schuetz JM; Leach S; Slack GW; Berry BR; Hu H; Sehn LH; Brooks-Wilson AR; Spinelli JJ
Haematologica; 2017 May; 102(5):e199-e202. PubMed ID: 28154089
[No Abstract] [Full Text] [Related]
12. Bilateral vocal cord paralysis following treatment with vincristine.
Naithani R; Dolai TK; Kumar R
Indian Pediatr; 2009 Jan; 46(1):68-9. PubMed ID: 19179723
[TBL] [Abstract][Full Text] [Related]
13. The clinician's decision of whether CHOP chemotherapy should be standard therapy for treatment of patients with diffuse histiocytic lymphoma.
Connors JM
Important Adv Oncol; 1990; ():227-33. PubMed ID: 2182521
[No Abstract] [Full Text] [Related]
14. Increased rituximab (R) doses eliminate increased risk and improve outcome of elderly male patients with aggressive CD20+ B-cell lymphomas: the SEXIE-R-CHOP-14 trial of the DSHNHL.
Clin Adv Hematol Oncol; 2014 Aug; 12(8 Suppl 16):8-9. PubMed ID: 25768993
[No Abstract] [Full Text] [Related]
15. Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma.
Musolino A; Boggiani D; Panebianco M; Vasini G; Salvagni S; Franciosi V; Ardizzoni A
Cancer; 2011 Mar; 117(5):964-73. PubMed ID: 20960528
[TBL] [Abstract][Full Text] [Related]
16. Outcomes with R-CEOP for R-CHOP-ineligible patients with diffuse large B-cell lymphoma are highly dependent on cell of origin defined by Hans criteria.
Rashidi A; Oak E; Carson KR; Wagner-Johnston ND; Kreisel F; Bartlett NL
Leuk Lymphoma; 2016 May; 57(5):1191-3. PubMed ID: 26397936
[No Abstract] [Full Text] [Related]
17. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial.
Vitolo U; Chiappella A; Ferreri AJ; Martelli M; Baldi I; Balzarotti M; Bottelli C; Conconi A; Gomez H; Lopez-Guillermo A; Martinelli G; Merli F; Novero D; Orsucci L; Pavone V; Ricardi U; Storti S; Gospodarowicz MK; Cavalli F; Sarris AH; Zucca E
J Clin Oncol; 2011 Jul; 29(20):2766-72. PubMed ID: 21646602
[TBL] [Abstract][Full Text] [Related]
18. Bilateral vocal fold paralysis following treatment with vincristine.
Praveen CV; De Lord CF
J Laryngol Otol; 2006 May; 120(5):423. PubMed ID: 16696885
[No Abstract] [Full Text] [Related]
19. Vincristine-induced vocal cord paralysis in a patient with acute lymphoblastic leukemia.
Bacon LC; Barnett MJ; Abou Mourad YR
Ann Hematol; 2012 Jun; 91(6):971-2. PubMed ID: 21976108
[No Abstract] [Full Text] [Related]
20. Addition of rituximab to reduced-dose CHOP chemotherapy is feasible for elderly patients with diffuse large B-cell lymphoma.
Shin HJ; Chung JS; Song MK; Kim SK; Choe S; Cho GJ
Cancer Chemother Pharmacol; 2012 May; 69(5):1165-72. PubMed ID: 22215473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
